Study Summary
This trial will study the effectiveness of two drugs, Veliparib and Lapatinib, for treating metastatic triple negative breast cancer.
- Metastatic Breast Cancer, Triple Negative Breast Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 6 Secondary · Reporting Duration: baseline to 4 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Combination of Veliparib + Lapatinib
1 of 1
Experimental Treatment
23 Total Participants · 1 Treatment Group
Primary Treatment: Combination of Veliparib + Lapatinib · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 22 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Stringer-Reasor, Erica M., Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, et al.. 2021. “An Open-label, Pilot Study of Veliparib and Lapatinib in Patients with Metastatic, Triple-negative Breast Cancer”. Breast Cancer Research. Springer Science and Business Media LLC. doi:10.1186/s13058-021-01408-9.
- Erica Stringer-Reasor 2014. "Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02158507.
Frequently Asked Questions
How many participants will be accepted in this clinical exploration?
"Unfortunately, recruitment for this research has already concluded. It was initially posted on September 1st 2014 and last reviewed on February 25th 2022. However, 2354 medical trials are presently recruiting participants with breast cancer while 42 studies related to the combination of Veliparib + Lapatinib currently require patients." - Anonymous Online Contributor
What maladies can be alleviated with the Veliparib + Lapatinib combination therapy?
"Combination of Veliparib + Lapatinib is a viable solution for postmenopausal women, breast cancer patients and those seeking advance directives." - Anonymous Online Contributor
Are there any preceding research examining the effects of Veliparib and Lapatinib administered together?
"Currently, 11 Combination of Veliparib + Lapatinib clinical trials are in Phase 3 with 42 ongoing studies. Though Lexington is the epicentre for these investigations, there exist 4371 sites globally conducting related research." - Anonymous Online Contributor
Are investigators currently adding participants to this research endeavor?
"This medical trial is no longer accepting new patients. Initially posted on September 1st, 2014 and last updated February 25th 2022, participants should look elsewhere for clinical trials. At present, 2354 studies are recruiting individuals with a diagnosis of breast cancer while 42 separate investigations need volunteers to combine veliparib + lapatinib medications." - Anonymous Online Contributor